Ignite Creation Date:
2024-06-16 @ 11:52 AM
Last Modification Date:
2024-10-26 @ 3:31 PM
Study NCT ID:
NCT06454890
Status:
NOT_YET_RECRUITING
Last Update Posted:
2024-06-12
First Post:
2024-06-06
Brief Title:
Clinical Study of Trop2 CAR-NK in the Treatment of RelapsedRefractory Non-Small Cell Lung Cancer NSCLC
Sponsor:
Henan Cancer Hospital
Organization:
Henan Cancer Hospital
Study Overview
Official Title:
An Investigator-initiated Trial Evaluating the Efficacy and Safety of Anti-Trop2 Universal CAR-NKU-CAR-NK Cells Therapy Combined With Chemotherapy for RelapsedRefractory Non-Small Cell Lung Cancer NSCLC
Status:
NOT_YET_RECRUITING
Status Verified Date:
2024-06
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
It is a single-center open-labeled single-arm non-randomized investigator-initiated trial evaluating the efficacy and safety of anti-Trop2 U-CAR-NK Cells Therapy combined with Chemotherapy for RelapsedRefractory Non-Small Cell Lung Cancer NSCLC
Detailed Description:
Who can participate Patients who were diagnosed with Non-Small Cell Lung Cancer and tumor cells expressing Trop2
How to conduct this study This study is an interventional clinical study The intervention in the trial is anti-Trop2 U-CAR-NK cells The administration time is 5 days after chemotherapy Patients were then evaluated efficacy and safety until 3 years after U-CAR-NK cells infusion
What are the possible benefits and risks of participating Benefits The effect of anti-tumor of NK cells may be used to disease control
Risks Subjects may have adverse reactions to the treatment These adverse reactions may include abnormal liver injury fever and possibly other unknown adverse reactions
Where is the study run Henan Cancer Hospital
How to conduct this study This study is an interventional clinical study The intervention in the trial is anti-Trop2 U-CAR-NK cells The administration time is 5 days after chemotherapy Patients were then evaluated efficacy and safety until 3 years after U-CAR-NK cells infusion
What are the possible benefits and risks of participating Benefits The effect of anti-tumor of NK cells may be used to disease control
Risks Subjects may have adverse reactions to the treatment These adverse reactions may include abnormal liver injury fever and possibly other unknown adverse reactions
Where is the study run Henan Cancer Hospital
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
False
Is a FDA Regulated Device?:
False
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None